Document And Entity Information Document Information [Table] Document Information [Line Items] Document Type Document Quarterly Report Document Period End Date Current Fiscal Year End Date Document Transition Report Entity Registrant Name Entity Incorporation, State or Country Code Securities Act File Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, City or Town Entity Address, State or Province Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security Trading Symbol Security Exchange Name Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Entity Shell Company Entity Common Stock, Shares Outstanding Entity Central Index Key Document Fiscal Year Focus Document Fiscal Period Focus Amendment Flag CONDENSED CONSOLIDATED BALANCE SHEETS Statement [Table] Statement [Line Items] Assets [Abstract] Assets Assets, Current [Abstract] Current assets: Cash and Cash Equivalent Cash and cash equivalents Debt Securities, Available-for-Sale, Current Marketable securities Fair Value Accounts Receivable, after Allowance for Credit Loss, Current Accounts receivable Accounts Receivable, after Allowance for Credit Loss, Current, Related Party [Extensible Enumeration] Prepaid Expense and Other Assets, Current Prepaid and other current assets Prepaid and other current assets Assets, Current Total current assets Current assets Property, Plant, and Equipment, after Accumulated Depreciation, Depletion, and Amortization Property and equipment, net Property and equipment, net Operating Lease, Right-of-Use Asset Operating lease right-of-use asset Equity Method Investments Investment in Angel Pharmaceuticals Other Assets, Noncurrent Other assets Assets Total assets Liabilities and Equity [Abstract] Liabilities and Stockholders' Equity Liabilities, Current [Abstract] Current liabilities: Accounts Payable, Current Accounts payable Operating Lease, Liability, Current Operating lease liability Accrued Liabilities, Current Accrued and other liabilities Accrued and other liabilities Liabilities, Current Current liabilities Total current liabilities Operating Lease, Liability, Noncurrent Operating lease liability Liabilities Total liabilities Commitments and Contingencies Commitments and contingencies (Note 15) Equity, Attributable to Parent [Abstract] Stockholders' equity: Preferred Stock, Value, Issued Preferred stock: $0.0001 par value; 10,000,000 shares authorized at June 30, 2026 and December 31, 2025; 0 shares issued and outstanding at each of June 30, 2026 and December 31, 2025 Common Stock, Value, Issued Common stock: $0.0001 par value; 290,000,000 shares authorized at June 30, 2026 and December 31, 2025; 84,120,944 and 74,696,629 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively Additional Paid in Capital Additional paid-in capital Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated other comprehensive loss Retained Earnings (Accumulated Deficit) Accumulated deficit Accumulated deficit Equity, Attributable to Parent Balance Balance Total stockholders' equity Stockholders' equity Liabilities and Equity Total liabilities and stockholders' equity Preferred Stock, Par or Stated Value Per Share Preferred stock, par value (in dollars per share) Preferred Stock, Shares Authorized Preferred stock, shares authorized Preferred Stock, Shares Issued Preferred stock, shares issued Preferred Stock, Shares Outstanding Preferred stock, shares outstanding Common Stock, Par or Stated Value Per Share Common stock, par value (in dollars per share) Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Shares, Issued Balance (in shares) Balance (in shares) Common stock, shares issued Common Stock, Shares, Outstanding Common stock, shares outstanding CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Operating Expenses [Abstract] Operating expenses: Research and Development Expense Research and development R&D expense General and Administrative Expense General and administrative Operating Expenses Total segment expense Total operating expenses Operating Income (Loss) Loss from operations Investment Income, Net Interest income and other expense, net Fair Value Adjustment of Warrants Change in fair value of warrant liability Change in fair value of warrant liability Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest Income (loss) before equity method investment Income (Loss) from Equity Method Investments Loss from equity method investment Share of loss from investments accounted for using the equity method Loss from equity method investment Net loss Net (loss) income Net income (loss) Earnings Per Share, Basic Net (loss) income per share, basic Earnings Per Share, Diluted Net loss per share, diluted Weighted Average Number of Shares Outstanding, Basic Shares used to compute net (loss) income per share, basic Weighted average common shares and pre-funded warrants outstanding used to compute basic net (loss) income per share Weighted Average Number of Shares Outstanding, Diluted Shares used to compute net loss per share, diluted Weighted average common shares and pre-funded warrants outstanding used to compute diluted net (loss) income per share Other Comprehensive Income (Loss), Net of Tax [Abstract] Other comprehensive (loss) income: OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax Unrealized loss on marketable securities Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Cumulative foreign currency translation adjustment Foreign currency translation adjustment Comprehensive Income (Loss), Net of Tax, Attributable to Parent Comprehensive (loss) income CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY Equity Components [Axis] Equity Component [Domain] Common Stock [Member] Common Stock Additional Paid-in Capital [Member] Additional Paid-In Capital AOCI Attributable to Parent [Member] Accumulated Other Comprehensive Loss Retained Earnings [Member] Accumulated Deficit Sale of Stock [Axis] Sale of Stock [Domain] Private Placement [Member] Registered Direct Offering Secondary offering of stock to the public. Follow-on Public Offering Follow-on Public Offering Over-Allotment Option [Member] Over-Allotment Option Sale of stock through an at-the-market equity offering program under a sales agreement. At-the-market offering 2024 Sales Agreement The gross value of stock issued during the period upon the exercise of warrants. Stock Issued During Period, Value, Warrants Exercised Issuance of common stock upon exercise of common stock warrants Number of shares issued during the period upon the exercise of warrants. Stock Issued During Period, Shares, Warrants Exercised Issuance of common stock upon exercise of common stock warrants (in shares) Number of Common Shares Issued Upon Exercise The gross value of stock issued during the period upon the exercise of pre-funded warrants. Stock Issued During Period, Value, Pre-Funded Warrants Exercised Issuance of pre-funded warrants upon exercise of common stock warrants Stock Issued During Period, Value, Stock Options Exercised Common stock issued upon exercise of stock options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Outstanding Options, Exercised Common stock issued upon exercise of stock options (in shares) Stock Issued During Period, Value, New Issues Gross proceeds from sale of stock Common stock issued Stock Issued During Period, Shares, New Issues Common shares issued in transaction Common stock issued (in shares) APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Stock-based compensation expense OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment, after Tax Unrealized loss on marketable securities CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Related and Nonrelated Parties [Axis] Related and Nonrelated Parties [Domain] Related Party [Member] Related party Cash Provided by (Used in) Operating Activity, Continuing Operation [Abstract] Cash flows from operating activities Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net (loss) income Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract] Adjustments to reconcile net (loss) income to net cash used in operating activities: Depreciation, Depletion and Amortization Depreciation and amortization Accretion (Amortization) of Discounts and Premiums, Investments Accretion related to marketable securities Share-Based Payment Arrangement, Noncash Expense Stock-based compensation Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities: Increase (Decrease) in Accounts Receivable Accounts receivable Increase (Decrease) in Prepaid Expense and Other Assets Prepaid and other current assets Increase (Decrease) in Other Noncurrent Assets Operating lease right-of-use asset Increase (Decrease) in Other Current Assets Other assets Increase (Decrease) in Accounts Payable Accounts payable Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities Accrued and other liabilities Increase (Decrease) in Operating Lease Liability Operating lease liability Cash Provided by (Used in) Operating Activity, Including Discontinued Operation Net cash used in operating activities Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract] Cash flows from investing activities Payments to Acquire Debt Securities, Available-for-Sale Purchases of marketable securities Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale Maturities of marketable securities Payments to Acquire Property, Plant, and Equipment Purchases of property and equipment Payments to Acquire Equity Method Investments Investment in Angel Pharmaceuticals Payment made for equity method investment Cash Provided by (Used in) Investing Activity, Including Discontinued Operation Net cash used in investing activities Cash Provided by (Used in) Financing Activity, Continuing Operation [Abstract] Cash flows from financing activities Proceeds from Issuance of Common Stock Proceeds from issuance of common stock in connection with follow-on public offering, net Proceeds from issuance of common stock Proceeds from Warrant Exercises Proceeds from the exercise of common stock warrants Proceeds from the exercise of common stock warrants (includes $4,960 in aggregate gross proceeds from related parties) Proceeds from Stock Options Exercised Proceeds from exercise of common stock options Cash Provided by (Used in) Financing Activity, Including Discontinued Operation Net cash provided by financing activities Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation Net increase in cash and cash equivalents Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation Cash and cash equivalents at end of the period Cash and cash equivalents at beginning of the period Supplemental Cash Flow Information [Abstract] Supplemental disclosures of cash flow information Capital Expenditures Incurred but Not yet Paid Purchases of property and equipment incurred but not paid Organization Nature of Operations [Text Block] Organization Summary of Significant Accounting Policies Basis of Presentation and Significant Accounting Policies [Text Block] Summary of Significant Accounting Policies Net Loss per Share Earnings Per Share [Text Block] Net Loss per Share Segments Segment Reporting [Text Block] Segments Fair Value Measurements. Fair Value Disclosures [Text Block] Fair Value Measurements Equity Method Investment Equity Method Investments and Joint Ventures Disclosure [Text Block] Equity Method Investment License and Collaboration Agreements Collaborative Arrangement Disclosure [Text Block] License and Collaboration Agreements Balance Sheet Components Supplemental Balance Sheet Disclosures [Text Block] Balance Sheet Components Warrants The entire disclosure for warrants and rights. Warrants And Rights Note Disclosure [Text Block] Warrants Common Stock The entire disclosure for common stock. Common Stock Note Disclosure [Text Block] Common Stock Stock Option Plans The entire disclosure for equity incentive plans Equity Incentive Plans Disclosure [Text Block] Stock Option Plans Stock-Based Compensation Share-Based Payment Arrangement [Text Block] Stock-Based Compensation Income Taxes Income Tax Disclosure [Text Block] Income Taxes Facility Lease Lessee, Operating Leases [Text Block] Facility Lease Commitments and Contingencies. Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Related Party Transactions Related Party Transactions Disclosure [Text Block] Related Party Transactions Basis of Accounting, Policy [Policy Text Block] Basis of Presentation Disclosure of accounting policy for the presentation of interim (unaudited) financial statements. Unaudited Interim Financial Information [Policy Text Block] Unaudited Interim Financial Information Use of Estimates, Policy [Policy Text Block] Use of Estimates Equity Method Investments [Policy Text Block] Investments in Equity Securities Concentration Risk, Credit Risk, Policy [Policy Text Block] Concentrations of Credit Risk and Other Risks and Uncertainties Disclosure of changes to significant accounting policies. Significant Accounting Policies [Policy Text Block] Significant Accounting Policies New Accounting Pronouncements, Policy [Policy Text Block] Recent Accounting Pronouncements Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Schedule of net (loss) income per share, basic and diluted Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of antidilutive securities excluded from calculation of diluted net loss per share Segment Reporting [Table Text Block] Schedule of segment net loss (income) by significant expense category Fair Value, Assets Measured on Recurring Basis [Table Text Block] Schedule of fair value of assets measured at fair value on a recurring basis, by level of fair value hierarchy Schedule of Available-for-Sale Securities Reconciliation [Table Text Block] Schedule of fair value of available for sale marketable securities Investments Classified by Contractual Maturity Date [Table Text Block] Schedule of remaining maturity by type of security Equity Method Investments [Table Text Block] Schedule of financial information of Angel Pharmaceuticals Co. Condensed Balance Sheet [Table Text Block] Schedule of balance sheet components Schedule of Options Indexed to Issuer's Equity [Table Text Block] Schedule of common stock shares reserved for future issuance Share-Based Payment Arrangement, Option, Activity [Table Text Block] Schedule of stock option activity Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Schedule of expenses relating to employee and non-employee stock-based awards Lessee, Lease, Description [Table] Lessee, Lease, Description [Line Items] Facility Lease Lease, Cost [Table Text Block] Schedule of components of lease expense Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Schedule of Minimum rental commitments Schedule of Related Party Transactions [Table Text Block] Schedule of common stock sold to related parties Presentation of information about the organization and basis of presentation. Organization [Table] Class of Warrant or Right [Axis] Class of Warrant or Right [Domain] Represents information pertaining to common stock warrants. Common Stock Warrants [Member] Common stock warrants The transaction group, which details the sale of common stock equity and the accompanying warrants to purchase common stock in connection with the company's Registered Direct Offering. Common Stock Shares and Common Stock Warrants [Member] Common Stock and Common Warrants Represents information pertaining to common warrants. Common Warrants [member] Common warrants Represents information pertaining to pre-funded warrants. Prefunded Warrants [member] Pre-funded warrants The transaction group, which details the sale of pre-funded warrants, and common warrants, to purchase common stock in connection with the company's Registered Direct Offering. Prefunded Warrants and Common Stock Warrants [Member] Pre-funded and Common Warrants Organization [Line Items] Organization Common Stock, Number of Shares, Par Value and Other Disclosure [Abstract] Public Offerings Class of Warrant or Right, Number of Securities Called by Warrants or Rights Warrants issued to purchase common shares Combined price per unit of share and warrants issued. Combined Offering Price For Shares And Warrants Combined offering price per share Combined offering price per share and warrants Shares Issued, Price Per Share Combined offering price per share Class of Warrant or Right, Exercise Price of Warrants or Rights Exercise price of warrants Exercise price expressed as price per unit of pre-funded warrants outstanding. Class of Warrant or Right, Exercise Price Per Prefunded Warrant Exercise price of pre-funded warrants Cash, Cash Equivalents, and Short-Term Investments Cash, cash equivalents and marketable securities Sale of Stock, Price Per Share Share price of stock issued Concentration Risk, Credit Risk, Uninsured Deposits Number of financial institutions in which cash and cash equivalents are deposited. Number Of Financial Institutions In Which Cash and Cash Equivalents Are Deposited Number of financial institutions in which cash and cash equivalents are deposited Earnings Per Share, Basic, by Common Class, Including Two-Class Method [Table] Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items] Earnings Per Share, Basic [Abstract] Net Loss Per Share, Basic and Diluted Net Income (Loss) Available to Common Stockholders, Basic [Abstract] Numerator: Net Income (Loss) Available to Common Stockholders, Basic Net (loss) income attributable to common stockholders, basic Warrant, Down Round Feature, Decrease in Net Income to Common Shareholder, Amount Gain from change in fair value of warrant liability Net Income (Loss) Available to Common Stockholders, Diluted Net (loss) income attributable to common stockholders, diluted Undistributed Earnings (Loss) Available to Common Shareholders, Diluted [Abstract] Denominator: Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants Weighted average shares issuable upon the exercise of the common warrants Antidilutive Security, Excluded EPS Calculation [Table] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Excluded from the calculation of diluted net loss per share, due to anti-dilutive effect Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Total shares of common stock equivalents Common shares issuable upon conversion of pre-funded warrants Common shares issuable upon conversion of pre-funded warrants Common shares issuable upon conversion of pre-funded warrants (included in calculation of basic and diluted EPS) Segment Reporting [Table] Segments [Axis] Segments [Domain] Represents the single reportable segment. Single Reportable Segment [member] Single Reportable Segment Segment Reporting [Line Items] Segments Number of Operating Segments Number of operating segments Number of Reportable Segments Number of reportable segments Compensation Expense, Excluding Cost of Good and Service Sold Compensation and benefits, excluding stock-based compensation The aggregate costs incurred for the operating segment in the production of goods for sale. Segment drug manufacturing costs Drug manufacturing Other Research and Development Expense Clinical trial Other General and Administrative Expense Outside general and administrative The expense in the period incurred with respect to protection provided by facilities and insurance entities against risks other than risks associated with production (which are allocated to cost of sales). Facilities And Insurance Facilities and insurance Other General Expense Other segment items Nonoperating Income (Expense) Non-operating income, net Fair Value, Recurring and Nonrecurring [Table] Measurement Frequency [Axis] Measurement Frequency [Domain] Fair Value, Recurring [Member] Fair Value, Recurring Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Domain] Fair Value, Inputs, Level 1 [Member] Level 1 Inputs Fair Value, Inputs, Level 2 [Member] Level 2 Inputs Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis Assets, Fair Value Disclosure [Abstract] Assets Cash and Cash Equivalents, Fair Value Disclosure Cash equivalents Assets, Fair Value Disclosure Total Assets Debt Securities, Available-for-Sale [Table] Financial Instrument [Axis] Financial Instruments [Domain] US Treasury Securities [Member] U.S. Treasury securities US Government Agencies Debt Securities [Member] U.S. Government agency securities Debt Securities, Available-for-Sale [Line Items] Available for sale marketable securities Current operations and the remaining maturity Debt Securities, Available-for-Sale, Fair Value to Amortized Cost, after Allowance for Credit Loss [Abstract] Fair value of available for sale marketable securities Debt Securities, Available-for-Sale, Amortized Cost, Current Amortized Cost Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Gross Unrealized Gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Gross Unrealized Losses Fair Value Measurements Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One Less than 1 Year Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Two 1-2 years Equity Method Investment [Table] Investment, Name [Axis] Investment, Name [Domain] Angel Pharmaceuticals, Ltd., an equity method investee of Corvus Pharmaceuticals. Angel Pharmaceuticals LTD Equity Method Investee [Member] Angel Pharmaceuticals, Ltd Legal Entity [Axis] All Entities [Member] Represents the information pertaining to equity financing. Equity Financing [Member] Equity financing Schedule of Equity Method Investments [Line Items] Equity Method Investment Proceeds from Issuance or Sale of Equity Aggregate Purchase Price Equity Method Investment, Ownership Percentage Corvus Pharmaceuticals equity ownership in subsidiary Equity ownership interest The Percentage of employee stock ownership plan (ESOP), equity reserve. Employee Stock Ownership Plan (ESOP), Equity Reserve, Percentage Equity reserved under employee stock ownership plan Equity Method Investment, Nonconsolidated Investee [Axis] Equity Method Investment, Nonconsolidated Investee [Domain] Equity Method Investment, Nonconsolidated Investee or Group of Investees [Member] Equity method investee Assets, Noncurrent Non-current assets Liabilities, Noncurrent Non-current liabilities Research and Development, Contract to Perform for Others [Table] Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Research and Development Arrangement, Contract to Perform for Others, Type [Domain] License Agreement Terms [Member] Licensing Agreement Scenario [Axis] Scenario [Domain] The member represent the Aggregate Potential Milestone Payments. Aggregate Potential Milestone Payments [Member] Aggregate potential milestone payments Counterparty Name [Axis] Counterparty Name [Domain] Represents the information pertaining to the Scripps Research Institute. Scripps Research Institute Represents the information pertaining to Vernalis (R&D) Limited. Vernalis (R&D) Limited Information pertaining to Monash License. Monash University Research and Development Arrangement, Contract to Perform for Others [Line Items] License and Collaboration Agreements Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross Annual licensing fee The amount purchased during the period under the license agreement milestone payment. License Agreement Milestone Payment Milestone payments Term of the research and development arrangement contract termination notice period, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Research And Development Arrangement Contract Termination Notice Period Early termination notice period Interest Receivable Interest receivable Other Prepaid Expense, Current Prepaid research and development manufacturing expenses Prepaid Rent Prepaid facility expenses Prepaid Insurance Prepaid insurance Other Assets, Current Other Property, Plant, and Equipment [Table] Long-Lived Asset, Class [Axis] Long-Lived Asset, Class [Domain] Equipment [Member] Laboratory equipment Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems and purchased software. Excludes in-development and internally developed software. Computer Equipment and Software, Purchased [Member] Computer equipment and purchased software Leasehold Improvements [Member] Leasehold improvements Construction in Progress [Member] Construction in progress Property, Plant, and Equipment [Line Items] Property and Equipment Property, Plant, and Equipment, before Accumulated Depreciation, Depletion, and Amortization Property and equipment, gross Property, Plant, and Equipment, Accumulated Depreciation, Depletion, and Amortization Less: accumulated depreciation and amortization Depreciation, Depletion and Amortization, Nonproduction Depreciation expense Amount of accrued liabilities clinical trial current. Accrued Liabilities Clinical Trial Current Accrued clinical trial expense Amount of accrued liabilities manufacturing current. Accrued Liabilities Manufacturing Current Accrued manufacturing expense Employee-related Liabilities, Current Personnel related Accrued Professional Fees, Current Accrued legal and accounting Other Accrued Liabilities, Current Other Class of Warrant or Right [Table] Class of Warrant or Right [Line Items] Warrants Adjustments to Additional Paid in Capital, Warrant Issued Class of Warrant or Right, Number of Securities Called by Each Warrant or Right Number of warrants exercised Class of Warrant or Right, Outstanding Warrants outstanding Amount of expense (income) related to adjustment to fair value of warrant liability. Change in fair value of warrant liabilities Change in fair value of warrant liability Stock, Class of Stock [Table] Jefferies LLC [Member] Jefferies LLC Jefferies LLC Statistical Measurement [Axis] Statistical Measurement [Domain] Maximum [Member] Maximum Scenario, Plan [Member] Scenario plan Class of Stock [Line Items] Common Stock Common Stock, Voting Rights Voting rights of common stock Dividends, Common Stock Dividends on common stock The percentage of compensation due to broker for underwriting commitments. Percent is calculated based on proceeds from securities sold. Underwriting Commitments, Percentage Sales agent fee percentage Class of Stock [Axis] Class of Stock [Domain] Derivative instrument whose primary underlying risk is tied to share prices. Pre-funded Warrant Equity [Member] Pre-funded warrants Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time. Shares Available for Future Option Grants Equity [Member] Shares available for future option grants Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option). Outstanding Options Equity [Member] Outstanding options An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock. Shares Reserved for Employee Stock Purchase Plan Equity [Member] Shares reserved for employee stock purchase plan Common Stock, Capital Shares Reserved for Future Issuance Common stock reserved for future issuance Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Plan Name [Axis] Plan Name [Domain] The entity's 2014 plan under which it may grant stock-based awards. 2014 Plan The entity's 2016 Equity Incentive Award Plan under which it may grant stock-based awards. 2016 Plan Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Stock Option Plans Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period Maximum exercise term Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent Exercise price of common stock grants, percentage of stock fair value Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Shares Available for Grant, Ending Balance Shares Available for Grant, Opening Balance Shares available for future option grants Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized Shares Available for Grant, Additional Shares Authorized Forfeited or unexercised shares under expired stock plan subject to re-issuance under current stock plan Share-Based Compensation Arrangement by Share-Based Payment Award, Other Share Increase (Decrease) Shares Available for Grant, Increase from Options Forfeited Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Outstanding Options, Ending Balance Outstanding Options, Opening Balance Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Outstanding Options, Granted Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Outstanding Options, Forfeited Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Outstanding Options, Weighted Average Exercise Price, Ending Balance Outstanding Options, Weighted Average Exercise Price, Opening Balance Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Outstanding Options, Weighted Average Exercise Price, Granted Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Outstanding Options, Weighted Average Exercise Price, Exercised Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Outstanding Options, Weighted Average Exercise Price, Forfeited Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Location, Statement of Income, Balance [Axis] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Stock-based compensation Share-Based Payment Arrangement, Expense Stock-based compensation expense Income Tax Expense (Benefit) Income tax benefits Building [Member] Represents the information related to office and lab space lease. Office And Lab Space Lease [Member] Office and lab space lease Represents the information related to third year of sublease Third Year of Sublease [Member] Third year of sublease Lessee Disclosure [Abstract] Lease Area of Real Estate Property Area of leased facility Lessee, Operating Lease, Term of Contract Lease term Lessee, Operating Lease, Existence of Option to Extend [true false] Option to Extend Lessee, Operating Lease, Renewal Term Lease extension period Operating Lease, Expense Sublease initial base monthly rent expense Lessee, Operating Lease, Existence of Option to Terminate [true false] Option to terminate Lease, Cost [Abstract] Costs of operating lease Operating Lease, Cost Operating lease costs Variable Lease, Cost Costs of non-lease components (previously common area maintenance) Lease, Cost Total operating lease cost Lessee, Operating Lease, Description [Abstract] Other Information Operating Lease, Payments Operating cash flows used for operating lease Operating Lease, Weighted Average Remaining Lease Term Remaining lease term Operating Lease, Weighted Average Discount Rate, Percent Discount rate Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract] Minimum Rental Commitments Lessee, Operating Lease, Liability, to be Paid, Year One 2026 Lessee, Operating Lease, Liability, to be Paid, Year Two 2027 Lessee, Operating Lease, Liability, to be Paid Total lease payments Lessee, Operating Lease, Liability, Undiscounted Excess Amount Less: imputed interest Operating Lease, Liability Total Related Party Transaction [Table] Related Party Transaction [Axis] Related Party Transaction [Domain] Represents information pertaining to services to support clinical trials. Services Support Clinical Trials [Member] Support clinical trials Represents information pertaining to ICON plc. Icon Plc [Member] ICON plc Represents information pertaining to Puissance Capital Management. Puissance Capital Management [Member] Puissance Capital Management Related Party Transaction [Line Items] Represents information pertaining to OrbiMed Advisors, LLC. Orbimed Advisors LLC [Member] OrbiMed Advisors, LLC Represents information pertaining to Richard A. Miller. Richard A Miller [Member] Richard A. Miller Represents information pertaining to William B. Jones. William B. Jones [Member] William B. Jones The number of issued warrants or rights which entitle the entity to receive future services in exchange for the unvested, forfeitable warrants or rights. Class of Warrant or Right, issued Number of Warrants Number of securities called by exercise of warrant. Number of Common Stock Warrants Exercised Number of Common Warrants Exercised Exercise price per share or per unit of warrants or rights outstanding paid on a cashless basis. Exercise price of warrants cashless basis Exercise price of warrants (cashless basis) Number of securities called by exercise of warrant and withheld to pay the exercise price fees. Number of Common Stock Warrant Shares Withheld For Payment of Fees Warrant shares exercised and withheld to pay exercise price N/A Non Rule 10b5-1 Arr Modified [Flag] Non-Rule 10b5-1 Arrangement Modified N/A Rule 10b5-1 Arr Modified Flag Rule 10b5-1 Arrangement Modified